As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

What is Wegovy? What are its side effects and what does it treat? - Panorama will look at the ‘game changing’ medication but ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy (semaglutide) at that time point.